ELE-101, a novel intravenous (IV) formulation of psilocin, is being developed by atai Life Sciences to offer a rapid, reliable, and shorter treatment option for Major Depressive Disorder (MDD). This synthetic formulation is designed to deliver therapeutic effects in approximately two hours, aiming for a more predictable and manageable patient experience.
The ongoing Phase 2a clinical trial, set to report results in the second half of 2024, is assessing the safety, tolerability, and efficacy of ELE-101 in 6-12 patients with MDD. This phase follows successful initial trials where ELE-101 demonstrated a favorable safety profile and consistent pharmacokinetic behaviors without serious adverse events.
Notably, ELE-101’s development is part of atai’s broader strategy to innovate mental health treatment by introducing short-duration, in-clinic psychedelic therapies. These developments are underpinned by atai’s significant investment in Beckley Psytech, enhancing their portfolio of rapid-acting psychedelic treatments.
For further details on atai Life Sciences and their initiatives, visit www.atai.life.